KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Current Leases (2019 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Current Leases for 8 consecutive years, with $45.7 million as the latest value for Q1 2026.

  • For Q1 2026, Current Leases fell 0.76% year-over-year to $45.7 million; the TTM value through Mar 2026 reached $45.7 million, down 0.76%, while the annual FY2025 figure was $45.5 million, 8.67% up from the prior year.
  • Current Leases hit $45.7 million in Q1 2026 for Alnylam Pharmaceuticals, roughly flat from $45.5 million in the prior quarter.
  • Across five years, Current Leases topped out at $46.1 million in Q2 2025 and bottomed at $41.2 million in Q2 2022.
  • Average Current Leases over 5 years is $42.9 million, with a median of $42.0 million recorded in 2022.
  • Year-over-year, Current Leases decreased 3.21% in 2024 and then grew 10.66% in 2025.
  • Alnylam Pharmaceuticals' Current Leases stood at $42.0 million in 2022, then decreased by 1.09% to $41.5 million in 2023, then increased by 0.91% to $41.9 million in 2024, then increased by 8.67% to $45.5 million in 2025, then grew by 0.31% to $45.7 million in 2026.
  • According to Business Quant data, Current Leases over the past three periods came in at $45.7 million, $45.5 million, and $44.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.